Trials / Completed
CompletedNCT00739232
Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016
Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016 Administered Orally to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a single ascending dose study of HSD-016 to provide the initial assessment of the safety, tolerability, how the drug is absorbed and eliminated, and its effect on the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSD-016 | |
| OTHER | placebo |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-08-21
- Last updated
- 2009-08-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00739232. Inclusion in this directory is not an endorsement.